Frontiers in Immunology (Mar 2024)
Diminished neutralizing activity against the XBB1.5 strain in 55.9% of individuals post 6 months COVID-19 mRNA booster vaccination: insights from a pseudovirus assay on 1,353 participants in the Fukushima vaccination community survey, Japan
- Tianchen Zhao,
- Tianchen Zhao,
- Yuta Tani,
- Yuta Tani,
- Chieko Makino-Okamura,
- Chieko Makino-Okamura,
- Morihito Takita,
- Morihito Takita,
- Chika Yamamoto,
- Chika Yamamoto,
- Eiki Kawahara,
- Eiki Kawahara,
- Eiki Kawahara,
- Toshiki Abe,
- Sota Sugiura,
- Hiroki Yoshimura,
- Hiroki Yoshimura,
- Taiga Uchiyama,
- Isato Yamazaki,
- Isato Yamazaki,
- Isato Yamazaki,
- Harumichi Ishigame,
- Harumichi Ishigame,
- Takaharu Ueno,
- Kazu Okuma,
- Masatoshi Wakui,
- Hidehiro Fukuyama,
- Hidehiro Fukuyama,
- Hidehiro Fukuyama,
- Hidehiro Fukuyama,
- Masaharu Tsubokura,
- Masaharu Tsubokura
Affiliations
- Tianchen Zhao
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Tianchen Zhao
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Yuta Tani
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Yuta Tani
- Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
- Chieko Makino-Okamura
- Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan
- Chieko Makino-Okamura
- Infectious Diseases Research Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
- Morihito Takita
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Morihito Takita
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Chika Yamamoto
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Chika Yamamoto
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Eiki Kawahara
- Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan
- Eiki Kawahara
- Infectious Diseases Research Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
- Eiki Kawahara
- Cell Integrative Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan
- Toshiki Abe
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Sota Sugiura
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Hiroki Yoshimura
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Hiroki Yoshimura
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Taiga Uchiyama
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- Isato Yamazaki
- Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan
- Isato Yamazaki
- Infectious Diseases Research Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
- Isato Yamazaki
- Cell Integrative Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan
- Harumichi Ishigame
- Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan
- Harumichi Ishigame
- Laboratory for Tissue Dynamics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
- Takaharu Ueno
- Department of Microbiology, Kansai Medical University, School of Medicine, Hirakata, Osaka, Japan
- Kazu Okuma
- Department of Microbiology, Kansai Medical University, School of Medicine, Hirakata, Osaka, Japan
- Masatoshi Wakui
- Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
- Hidehiro Fukuyama
- Division of Immunology, Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, Japan
- Hidehiro Fukuyama
- Infectious Diseases Research Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
- Hidehiro Fukuyama
- Cell Integrative Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan
- Hidehiro Fukuyama
- INSERM EST, Strasbourg, France
- Masaharu Tsubokura
- General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Tokyo, Japan
- Masaharu Tsubokura
- Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
- DOI
- https://doi.org/10.3389/fimmu.2024.1337520
- Journal volume & issue
-
Vol. 15
Abstract
This study investigates the neutralizing activity against the XBB1.5 variant and the ancestral strain in a population post-bivalent vaccination using a pseudo virus assay validated with authentic virus assay. While bivalent booster vaccination and past infections enhanced neutralization against the XBB 1.5 strain, individuals with comorbidities showed reduced responses. The study suggests the need for continuous vaccine updates to address emerging SARS-CoV-2 variants and highlights the importance of monitoring real-world immune responses.
Keywords
